Rhabdomyosarcoma Clinical Trial
Official title:
A Phase II Trial of Dasatinib in Advanced Sarcomas
This study will examine the response rate and the 6-month progression-free survival rates of subjects with advanced sarcoma treated with dasatinib.
Further details provided by SARC (Sarcoma Alliance for Research through Collaboration):
Treatment: Subjects take Dasatinib twice daily by mouth for 28 days per 28 day cycle.
Subjects will be seen for interim medical history, physical exam and laboratory studies prior
to each cycle. Subjects will undergo tumor imaging every 2 months (8 weeks) for the first 6
months and approximately every 3 months thereafter while on treatment.
A blood sample for collection of specimens with which to later study serum level of Dasatinib
and effects on biomarkers of drug activity will be obtained approximately 2 to 4 weeks after
the start of treatment.
Central collection of archival tumor with which to later study the frequency of expression
and/or mutation of kinases inhibited by dasatinib will occur.
Subjects will be followed for approximately every 3 months until 2 years from registration
and then approximately yearly until 5 years from registration.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04388839 -
Evolutionary Therapy for Rhabdomyosarcoma
|
Phase 2 | |
| Withdrawn |
NCT04906876 -
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
|
Phase 2 | |
| Completed |
NCT01674101 -
Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy
|
N/A | |
| Completed |
NCT00520936 -
A Study of Pemetrexed in Children With Recurrent Cancer
|
Phase 2 | |
| Completed |
NCT03655587 -
Impact of an Orthotic Intervention in Children With Peripheral Neuropathy
|
N/A | |
| Recruiting |
NCT06094101 -
Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04625907 -
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04095221 -
A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma
|
Phase 1/Phase 2 | |
| Completed |
NCT01661400 -
Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04337177 -
Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT02945800 -
Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma
|
Phase 2 | |
| Not yet recruiting |
NCT06029465 -
Analyzing Engagement Trends in Rhabdomyosarcoma Clinical Trials
|
||
| Terminated |
NCT02536183 -
A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT00592592 -
Proton RT for the Treatment of Pediatric Rhabdomyosarcoma
|
Phase 2 | |
| Completed |
NCT00187174 -
Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors
|
Phase 1 | |
| Completed |
NCT01505569 -
Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
|
N/A | |
| Active, not recruiting |
NCT03220035 -
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
| Completed |
NCT05093322 -
A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT04956198 -
Drug Sensitivity and Mutation Profiling
|
||
| Recruiting |
NCT04791228 -
A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors
|
Phase 2 |